277 related articles for article (PubMed ID: 17158033)
1. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients.
Roberts JA; Webb SA; Lipman J
Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.
Lin JC; Yeh KM; Peng MY; Chang FY
J Microbiol Immunol Infect; 2001 Jun; 34(2):131-7. PubMed ID: 11456359
[TBL] [Abstract][Full Text] [Related]
3. Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilli.
Toltzis P; Dul M; O'Riordan MA; Salvator A; Rosolowski B; Toltzis H; Blumer JL
Pediatr Infect Dis J; 2003 Feb; 22(2):109-14. PubMed ID: 12586972
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
McKinnon PS; Paladino JA; Schentag JJ
Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
[TBL] [Abstract][Full Text] [Related]
5. Current guidelines for the treatment of severe pneumonia and sepsis.
Bodmann KF
Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
[TBL] [Abstract][Full Text] [Related]
6. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.
Boselli E; Breilh D; Duflo F; Saux MC; Debon R; Chassard D; Allaouchiche B
Crit Care Med; 2003 Aug; 31(8):2102-6. PubMed ID: 12973166
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the effectiveness of ceftazidime in treatment of nosocomial infections in children].
Czerwionka-Szaflarska M; Sobkowiak E
Pediatr Pol; 1996 Jul; 71(7):605-7. PubMed ID: 8803464
[TBL] [Abstract][Full Text] [Related]
8. The choice of antibacterial drugs.
Med Lett Drugs Ther; 1998 Mar; 40(1023):33-42. PubMed ID: 9549552
[No Abstract] [Full Text] [Related]
9. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
[TBL] [Abstract][Full Text] [Related]
10. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms.
Niederman MS
Clin Infect Dis; 2006 Jan; 42 Suppl 2():S72-81. PubMed ID: 16355320
[TBL] [Abstract][Full Text] [Related]
11. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Chapman TM; Perry CM
Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
[TBL] [Abstract][Full Text] [Related]
12. [Antibiotic strategies in the treatment of infection in critically ill patients].
Schierbeck J; Kolmos HJ
Ugeskr Laeger; 2007 Feb; 169(8):699-702. PubMed ID: 17313920
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Bassetti M; Righi E; Rosso R; Mannelli S; Di Biagio A; Fasce R; Pallavicini FB; Marchetti F; Viscoli C
Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
[TBL] [Abstract][Full Text] [Related]
14. Use of linezolid in critically ill patients admitted to intensive care units.
Rodríguez O; Alvarez F; Oltra R; Cereijo E; Latorre MM; Martínez H;
Rev Esp Quimioter; 2009 Jun; 22(2):68-75. PubMed ID: 19554485
[TBL] [Abstract][Full Text] [Related]
15. Cefepime versus ceftazidime for treatment of pneumonia.
Konstantinou K; Baddam K; Lanka A; Reddy K; Zervos M
J Int Med Res; 2004; 32(1):84-93. PubMed ID: 14997712
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
[TBL] [Abstract][Full Text] [Related]
18. Treating serious infections: focus on cefepime.
Wong-Beringer A
Pharmacotherapy; 2004 Dec; 24(12 Pt 2):216S-23S. PubMed ID: 15585451
[TBL] [Abstract][Full Text] [Related]
19. [Strategies targeted at optimising antimicrobial therapy in critically ill patients].
Eggimann P; Oddo M; Voirol P; Zanetti G; Chioléro R
Rev Med Suisse; 2005 Dec; 1(45):2928-32. PubMed ID: 16425950
[TBL] [Abstract][Full Text] [Related]
20. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
